TY - JOUR T1 - Regarding minimal clinically relevant differences for superiority margins JF - BMJ Evidence-Based Medicine JO - BMJ EBM SP - 80 LP - 80 DO - 10.1136/bmjebm-2018-110925 VL - 23 IS - 2 AU - Patrick S Phelan Y1 - 2018/04/01 UR - http://ebm.bmj.com/content/23/2/80.abstract N2 - Being familiar with the relevant previous work of authors Shafiq and Malhotra, I read with interest their recent letter with Gamad concerning reporting of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS).1 That trials such as CANTOS continue to be reported with claims of superiority without consideration of asymmetry in error margins … ER -